Health

Gene-Edited Therapy Achieves 82% Remission in Leukemia Trial

Is this a breakthrough offering hope for incurable cancer, or a risky treatment with sobering long-term outcomes?

Published DEC 9 2025

Gene-Edited Therapy Achieves 82% Remission in Leukemia Trial

Story

Above: Alyssa Tapley, accompanied by her family, at the 2025 Breakthrough Prize Ceremony at Barker Hangar in Santa Monica, California, on April 5, 2025. Image credit: Craig T Fruchtman/Contributuor/Getty Images

The Facts

A clinical trial involving nine children and two adults with T-cell acute lymphoblastic leukemia at Great Ormond Street Hospital and King's College Hospital showed that 82% of patients achieved "deep remission" after receiving BE-CAR7 treatment, enabling them to proceed to stem cell transplant without detectable disease.
BBC News
The Standard
The BE-CAR7 therapy uses base editing technology to modify healthy donor T-cells through three key DNA changes: disabling existing receptors to make them universal, removing the CD7 marker to prevent self-destruction and adding a chimeric antigen receptor to target cancerous T-cells.
News Medical
Sky News
Alyssa Tapley from Leicester, who was 13 when she became the first patient to receive the base-edited treatment in 2022, is now 16 and disease-free, with plans to pursue an apprenticeship in biomedical science and eventually work in blood cancer research.
BBC News
Independent
The treatment showed that 64% of patients remain disease-free, with some patients now three years post-treatment and off medication. Side effects, including low blood counts, cytokine release syndrome and rashes, were reported as manageable by researchers.
News Medical
The Standard
Base editing is an advanced form of CRISPR technology that changes single letters of DNA code without cutting the DNA strand, reducing the risk of chromosomal damage while allowing scientists to precisely modify the genetic instructions within living cells.
Medicalxpress
The Times of India
The researchers say the new treatment is for those who do not respond to standard therapies. This discovery was published in the New England Journal of Medicine on Monday and presented at the 67th American Society of Hematology Annual Meeting.
Independent
Stirling News
NEJM

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

Gene-edited therapy BE-CAR7 represents a monumental breakthrough in cancer treatment, achieving 82% deep remission rates for previously incurable T-cell leukemia. This off-the-shelf treatment uses base editing to transform donor immune cells into cancer-fighting weapons, offering real hope where only palliative care existed before.

NEJM

Narrative B

While this may indeed offer promise, it could also face sobering long-term limits. Even though 82% of patients reached deep remission, unintended effects from gene-editing and immune-manipulation remain substantial. The “off-the-shelf” edited T-cells carry risks such as prolonged immunosuppression, infections, marrow suppression and in some cases immune escape of leukemia via CD7-negative variants — meaning relapse may still occur.

Blood Journals Portfolio